ESMO Immuno-Oncology 2024 Congress: Welcome!

(48)

ESMO Immuno-Oncology Congress 2023: Michele Maio \u0026 Aurélien Marabelle on reasons to submit your work

(1:49)

Breast and gynecological cancer highlights at ESMO Immuno-Oncology 2022

(1:2)

ESMO Immuno-Oncology 2024 Congress: an event to explore challenges and emerging trends in the field

(1:59)

Deciphering Immuno-Oncology: Targeting Cellular Mechanisms of the Tumor Immune Response

(1:2:29)

Immuno-Oncology Symposium - Part 1

(2:16:45)

Today Immunotherapy can cure even fourth stage cancer: Dr Dattatreyudu Nori

(8:46)

Lecture on Cancer [ Coffee/ cancer; EV Pembro; Censoring] to UCSF Fresno

(55:18)

ESMO Course in medical oncology for medical students: why should you apply?

(3:30)

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC

(5:18)

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

(4:17)

The Three Es of Immunoediting

(3:14)

ESMO 2023 Highlights

(3:12)

Expert video report on immunotherapy novelties in the management of patients with endometrial cancer

(8:32)

ESMO Immuno-Oncology 2024 Congress Experts in the field invite you to share your research.

(1:42)

ESMO Immuno-Oncology Congress 2023: Michele Maio \u0026 Aurélien Marabelle on why you should register

(1:14)

ESMO Immuno-Oncology Congress 2023: Why young oncologists should attend

(2:1econd)

ESMO Immuno-Oncology 2024: Experts in different tumour types explain the importance of this congress

(1:38)

ESMO Immuno-Oncology 2024: Congress Experts in the field invite you to share your research.

(1:46)

ESMO Handbook of Immuno-Oncology

(1:15)

ESMO 2024 – Dr Meredith McKean

(7:16)

Kohei Shitara, ESMO 2019 - Immuno-oncology in gastric/gastroesophageal junction cancer

(5:1econd)

ESMO Immuno-Oncology 2024 Congress M. Maio, A. Marabelle and I. Svane invite you to attend

(2:)

ESMO Immuno-Oncology Congress 2023: Access to all the latest updates in immuno-oncology

(1:37)

POCHI: pembrolizumab, CAPOX and bevacizumab in pMMR/MSS CRC at ESMO 2024

(56)

ESMO 2024

(2:54)